NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

Merck & Co.'s Keytruda Wins Canadian Nod As Adjuvant Therapy For
(MT Newswires)
Merck & Co. (MRK.PA) said Tuesday that it received Health Canada's approval for Keytruda's use as an adjuvant treatment for adults and children, aged 12 and above, with stage 2B or 2C melanoma after complete resection.

Melanoma is the least common type of all skin cancers but the most serious due to its high risk of spreading into any organ. In Canada, there are around 9,000 individuals diagnosed with melanoma in 2022.

The approval is based on the results of the late-stage Keynote-716 trial, in which the anticancer drug significantly improved recurrence-free survival. At the time of a 14.3 months follow-up, about 11% of patients treated with Keytruda had a recurrence or died versus 17% in placebo.